OncoMatch/Clinical Trials/NCT05753826
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Is NCT05753826 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Fuzuloparib for ovarian neoplasms.
Treatment: Adebrelimab · Fuzuloparib — This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
recurrence within less than 6 months after the last treatment with platinum-containing chemotherapy
Cannot have received: immune checkpoint inhibitor
prior treatment with known or probable immune checkpoint inhibitors
Lab requirements
Blood counts
HB≥100g/L, WBC≥3×10^9/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L (no blood transfusion within 14 days)
Kidney function
Serum Cr≤1.5x ULN
Liver function
BIL ≤1.5x ULN; ALT and AST≤2.5x ULN, ALT and AST≤5x ULN in patients with liver metastases
Cardiac function
No severe heart disorders; APTT ≤ 1.5x ULN, PT ≤ 1.5x ULN, INR ≤ 1.5x ULN unless on anticoagulation and within expected range; No cardiac insufficiency above NYHA grade 2, unstable angina, acute MI within 1 year, clinically significant arrhythmias requiring treatment, QTc>470ms
Major organ functions are normal and meet the following criteria: (1) Blood routine inspection standards must meet: (no blood transfusion within 14 days)a.HB≥100g/L, b. WBC≥3×10^9/L c. ANC≥1.5×10^9/L, d.PLT≥100×10^9/L; (2) Biochemical examination must meet the following standards: a. BIL ≤1.5 times the upper limit of normal (ULN); b. ALT and AST≤2.5×ULN, ALT and AST≤5×ULN in patients with liver metastases; c. Serum Cr≤1.5×ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 times ULN, prothrombin time (PT) ≤ 1.5 times ULN, international normalized ratio (INR) ≤ 1.5 times ULN, unless the patient is receiving anticoagulation, as long as PT or APTT is within the expected range of anticoagulant use; No severe heart, lung, liver or kidney disorders
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify